Johnson and Johnson (NEO:JNJ)
Historical Stock Chart
From Oct 2019 to Oct 2024
ACR/REF, Announce $3 Million Grant from Centocor to Bolster the Future of
Rheumatology
- Program Designed to Encourage Research and Specialization in Rheumatology -
ATLANTA and MALVERN, Pa., Oct. 27 /PRNewswire/ -- The American College of
Rheumatology Research and Education Foundation (REF) today announced a program
designed to encourage research careers in rheumatic medicine. This new program
-- made possible by a $3 million grant from Centocor -- supports a fellowship
program for young physicians.
Through their multi-year grant, Centocor will support the REF's Physician
Scientist Development Award program. This award supports the independent, but
mentored, research of physicians within a clinical or research setting.
"By supporting the careers of promising, young researchers and their
cutting-edge initiatives, the partnership between the REF and Centocor will
ultimately provide superior care for the millions of people suffering from
rheumatic diseases." said REF President Joseph Golbus, MD.
As Americans are living longer and growing older in record numbers, the need for
rheumatic care is greater than ever. This comes at a time when a significant
number of rheumatology professionals are planning their own retirement. It is
estimated that 20% of rheumatologists are expected to retire in the next three
to five years, creating a shortage of specialists to care for patients with
rheumatic diseases. The REF and Centocor, Inc. are committed to working together
to ensure that patients will continue to receive the specialized care they need,
and that vital research designed to investigate the causes, improve treatment,
and work toward the prevention and cure of rheumatic diseases will continue.
"We are proud to support the REF on this important initiative to expand the
field of rheumatology," said Tony Vernon, president of Centocor. "Centocor's
support of the REF underscores our mutual commitment to improving the lives of
patients battling rheumatic diseases. Together, we're dedicated to leading the
future of rheumatology through innovative research and fellowship programs."
About Centocor
Centocor is a leading biopharmaceutical company that creates, acquires and
markets cost-effective therapies that yield long-term benefits for patients and
the healthcare community. The company is dedicated to the research and
development of treatments for a wide range of Immune-Mediated Inflammatory
Disorders such as arthritis, inflammatory skin diseases and cancer. Centocor's
products, developed primarily through monoclonal antibody technology, help
physicians deliver innovative treatments to improve human health and restore
patients' quality of life. Centocor is a wholly-owned subsidiary of Johnson &
Johnson, the worldwide manufacturer of healthcare products.
About the ACR Research and Education Foundation
The mission of the American College of Rheumatology Research and Education
Foundation, a 501(c)(3) organization, is to attract and support the training and
development of qualified physicians and other health care professionals, and to
support research designed to investigate the causes, improve treatment, and work
toward the prevention and cure of rheumatic diseases. For more information on
the REF, visit http://www.rheumatology.org/ref.
For more information, contact:
ACR Research and Education Foundation Centocor, Inc.
Sara Loveless Michael Parks
(404) 633-3777 (610) 240-4010
(610) 597-4940
Centocor
DATASOURCE: American College of Rheumatology Research and Education Foundation;
CONTACT: Sara Loveless of ACR Research and Education Foundation,
+1-404-633-3777, ; Michael Parks of Centocor, Inc.,
+1-610-240-4010, cell - +1-610-597-4940
Web site: http://www.rheumatology.org/ref